- Home
- CYTK
as of 12-19-2025 1:35pm EST
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 8.0B | IPO Year: | 2004 |
| Target Price: | $78.94 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.31 - $69.33 | Next Earning Date: | 11-05-2025 |
| Revenue: | $87,211,000 | Revenue Growth: | 2609.26% |
| Revenue Growth (this year): | 361.33% | Revenue Growth (next year): | 65.14% |
AI-Powered CYTK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
EVP Research & Development
Avg Cost/Share
$61.24
Shares
2,200
Total Value
$134,728.00
Owned After
138,552
SEC Form 4
EVP, Chief Commercial Officer
Avg Cost/Share
$65.96
Shares
1,042
Total Value
$68,730.32
Owned After
50,660
SEC Form 4
EVP Research & Development
Avg Cost/Share
$63.89
Shares
2,200
Total Value
$140,558.00
Owned After
138,552
SEC Form 4
Director
Avg Cost/Share
$63.90
Shares
8,750
Total Value
$559,125.00
Owned After
74,578
SEC Form 4
Director
Avg Cost/Share
$66.72
Shares
28,064
Total Value
$1,872,430.08
Owned After
9,977
SEC Form 4
Director
Avg Cost/Share
$66.80
Shares
2,150
Total Value
$143,620.00
Owned After
18,542
SEC Form 4
Director
Avg Cost/Share
$64.73
Shares
5,000
Total Value
$323,650.00
Owned After
22,933
SEC Form 4
EVP Research & Development
Avg Cost/Share
$66.45
Shares
2,200
Total Value
$146,190.00
Owned After
138,552
SEC Form 4
Director
Avg Cost/Share
$65.08
Shares
5,175
Total Value
$336,789.00
Owned After
9,977
SEC Form 4
EVP Research & Development
Avg Cost/Share
$59.55
Shares
2,295
Total Value
$136,667.25
Owned After
138,552
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | Dec 16, 2025 | Sell | $61.24 | 2,200 | $134,728.00 | 138,552 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | Dec 8, 2025 | Sell | $65.96 | 1,042 | $68,730.32 | 50,660 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Dec 2, 2025 | Sell | $63.89 | 2,200 | $140,558.00 | 138,552 | |
| HENDERSON JOHN T | CYTK | Director | Dec 2, 2025 | Sell | $63.90 | 8,750 | $559,125.00 | 74,578 | |
| Kaye Edward M. MD | CYTK | Director | Dec 1, 2025 | Sell | $66.72 | 28,064 | $1,872,430.08 | 9,977 | |
| Harrington Robert Arthur | CYTK | Director | Dec 1, 2025 | Sell | $66.80 | 2,150 | $143,620.00 | 18,542 | |
| PARSHALL B LYNNE | CYTK | Director | Nov 19, 2025 | Sell | $64.73 | 5,000 | $323,650.00 | 22,933 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Nov 18, 2025 | Sell | $66.45 | 2,200 | $146,190.00 | 138,552 | |
| Kaye Edward M. MD | CYTK | Director | Nov 11, 2025 | Sell | $65.08 | 5,175 | $336,789.00 | 9,977 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Nov 4, 2025 | Sell | $59.55 | 2,295 | $136,667.25 | 138,552 |
Compare CYTK vs Leading Stocks
See how CYTK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.